Story
The Full Story
Lyka Labs is a 49-year-old Mumbai pharmaceutical company whose narrative has lurched from near-insolvency (FY2020 ₹53.6 Cr loss, debts assigned to an Asset Reconstruction Company), to euphoric rescue (Ipca Laboratories acquiring a 26.70% joint-promoter stake in late 2021), to an FY2022 anomaly year where revenue hit ₹194 Cr and net profit ₹38 Cr on "higher-realization products", and then straight back into losses. Across every annual report since FY2021 the phrase "Your Company does not perceive any risks or concerns other than those common to the industry" has been copied forward almost verbatim — even as the business cycled through a founder's death, a debt-restructuring ARC deal, a 52% operating-margin outlier, a full promoter change, and a Q2 FY26 operating-margin collapse to -6.93%. What changed most is not the business; it is who controls the story. The Gandhis used to tell it. Ipca now shares the pen, and the current chapter — FertiNova, veterinary healthcare and a Europe lyophilization push — is being sold to shareholders while Q2 FY26 prints a ₹3.36 Cr loss and a 461% sequential collapse in quarterly PAT.
1. The Narrative Arc
The arc has three acts. Act I (FY2018–FY2021): near-death. Revenue collapses from ₹110 Cr to ₹60 Cr, the founder dies, bank debts are assigned to an asset reconstruction company, and the company writes off ₹27 Cr of exceptional items in FY20. Act II (FY2022): rescue and euphoria. Ipca Laboratories' open offer concludes at 26.70% and Lyka reports the best year in its modern history — revenue ₹194 Cr, operating margin 52%, net profit ₹38 Cr. Management credits "sales of higher-realisation products"; the 52% OPM was never achieved before and has never been achieved since. Act III (FY2023–present): the new owners redraw the map. Chairmanship passes to an independent director (Babulal Jain), Ipca executives Prashant Godha and Shashil Mendonsa join the board, and the strategy pivots three times in three years — veterinary (Agilis, 2023), then FertiNova IVF/ART (2025), then a Lyka Exports merger (NCLT-approved March 2026), all while Q2 FY26 operating margin turns negative again.
2. What Management Emphasized — and Then Stopped Emphasizing
Three pivots are clear from the heatmap. Russia and Ukraine: in FY2020 management named four specific Russia-market dupe products it planned to launch ("Mulberry's Secret", "UPSIZE Cream", "Miracle Glow", "Titan Gel"). That ambition was never mentioned again after FY2021. Cosmeceutical / P2P: the FY20–22 outlooks leaned heavily on cosmeceuticals and "P to P" (principal-to-principal) contract work; by FY2025 the entire topic has vanished from the narrative. IARC / debt restructuring: the defining story of FY2020 — "Master Restructuring Agreement with IARC … now free from Bank debts" — is never revisited; shareholders are simply told the debt-equity ratio has fallen, without any acknowledgement that the underlying debt was parked with an ARC rather than repaid to a bank.
What arrived instead: the Ipca partnership (dominates FY22 onward), animal healthcare via the Agilis acquisition (FY23 onward), and in FY25 a brand-new division — FertiNova — targeting IVF and women's health "over the next three years through innovation and strategic partnerships". Europe and UK regulated-market ambitions, dormant for four years, also returned in FY25 coupled to the 50%-capacity lyophilization expansion.
3. Risk Evolution
The risk section is a masterclass in static boilerplate. From FY2021 through FY2025 the "Risks and Concerns" paragraph reads almost identically every year: "Your Company does not perceive any risks or concerns other than those that are common to the industry such as regulatory risks, exchange risk, cyber risks and other commercial and business related risks." That sentence was copied forward through a 30x swing in operating profit and a full ownership change.
The telling admission appears only in the remuneration schedule buried deep in the FY25 notice — in Item 8 (re-appointment of CFO Yogesh Shah), the Company finally concedes under "Reasons for inadequate profits": "The Company's margins are under pressure due to competition from small manufacturers as well as lower demand for products manufactured by the Company." This is the most candid risk statement in six years of filings, and it is hidden in a schedule explaining why the CFO's bonus still needs shareholder approval.
What also disappears is the FY20 disclosure that 5.3% of promoter shares were pledged. By FY23 the original Gandhi promoter group has been substantially diluted by Ipca entering at 26.70% and then converting warrants. The pledge risk goes away because the family stake goes away.
4. How They Handled Bad News
The FY2023 slump is the cleanest case study. After FY2022's blockbuster (revenue ₹194 Cr, PAT ₹38 Cr, OPM 52%), FY2023 revenue collapsed to ₹93 Cr and swung to a ₹13 Cr loss. Management's single-sentence explanation:
"Decrease in Operating profit margin due to profit for the year is lower than the previous year as previous year higher realization products are sold."
Why this matters: the entire FY22 profit thesis — the one that convinced shareholders the Ipca acquisition had unlocked value — is retroactively re-categorised as one-time sales of higher-realization products. There is no disclosure of what those products were, what drove realization higher, or why they could not be repeated. The 52% operating margin was never going to be the new base; management knew it, and the disclosure confirms it only in hindsight.
The FY2020 crisis was handled with more candour, though the context helped — the founder had just died and the numbers were unmissable. The Directors' Report explicitly lists "writing off non-movable stocks, writing off long outstanding debtors, writing off non-recoverable advance amount and substantial amount of interest payable to International Asset Reconstruction Company (IARC)." That level of specificity has not reappeared since. The FY26 downturn — a 461% sequential collapse in quarterly PAT — has, at the time of writing, no equivalent management explanation in annual filings yet; the FY25 MDA continues to project the Company will "do reasonably well in financial terms … within the next couple of years."
5. Guidance Track Record
Lyka does not issue numeric guidance — consistent with most small-cap Indian pharma. What it does make are qualitative commitments in the MDA's "Outlook" section. The table below tracks the meaningful ones.
Credibility score: 3 out of 10. Lyka makes few quantified promises, which limits the downside. But the qualitative commitments that are made — Europe/UK regulated approvals, the 50% lyophilization capacity boost, the Russian cosmeceutical launches — have been repeatedly deferred, re-promised, or silently abandoned. The one large promise that did pay off (Ipca-driven lyophilized injectable export growth) came with a single outlier year of profitability that has not been repeatable. Shareholders who held through the Ipca acquisition are still waiting for the thesis to show up in sustained earnings.
6. What the Story Is Now
The story today is "Ipca's turnaround project, still underway." Ipca Laboratories now owns 40.98% of Lyka, controls two board seats (Prashant Godha and Shashil Mendonsa — the latter simultaneously Ipca's President, International Marketing), and drives the related-party transaction framework (the FY26 RPT limit with Ipca alone is ₹50 Cr, plus ₹25 Cr with Makers Laboratories). The Gandhi family is still represented by Kunal Gandhi as MD/CEO, but the Chairman is an Ipca-era independent director and the CFO has been given a fresh three-year term at the FY25 AGM with the explicit rider that "in case the Company has no profits or its profits are inadequate, the remuneration … shall be paid as Minimum Remuneration." The Company is telling you, in Schedule V boilerplate, that it expects profits to be inadequate.
What management now emphasises: lyophilization capacity +50% (project slipping to FY26), FertiNova as a new growth vertical, veterinary healthcare scaling after the Agilis acquisition, and an ESOP scheme covering 2% of paid-up capital for employees-and-KMP-but-not-promoters — suggesting retention pressure inside a company that has churned through three Company Secretaries in six years.
What management has quietly stopped emphasising: the Russian/Ukrainian cosmeceutical business, the P2P contract-manufacturing playbook that was the FY20–FY21 lifeline, the 2020 preferential issue that failed because a pledgee did not approve, and — most importantly — any honest reconciliation of why FY2022 was worth ₹38 Cr and FY2023 through FY2025 were collectively worth roughly ₹-8 Cr.